Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

Professor Matthew Snape

The University of Oxford  professors have been named National Institute of Health Research (NIHR) Senior Investigators in recognition of being “among the most prominent and prestigious researchers funded by the NIHR and the most outstanding leaders of patient and people-based research within the NIHR research community”.

The researchers named NIHR Senior Investigator are:

  • Prof Peter McCulloch, of the Nuffield Department of Surgical Science, founded the QRSTU research group, which is dedicated to studies of quality and safety interventions in surgery, and has worked with the NHS Institute and the Health Foundation on work to make operating theatres safer.
  • Prof John Powell, of the Nuffield Department of Primary Care Health Sciences, combines his academic career with a role as Consultant Clinical Adviser at NICE, where he advises the NHS on the safe adoption of surgical and other interventional procedures.
  • Prof Jonathan Rees, of the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, combines a clinical role as a Consultant Orthopaedic Shoulder Surgeon with a research programme on ‘Improving Orthopaedic Patient Outcomes and Treatment Delivery’.
  • Prof Matthew Snape, of the Department of Paediatrics, is an Associate Professor in General Paediatrics and Vaccinology at the Oxford Vaccine Group, whose research focuses principally on vaccines against meningococcal, pneumococcal, influenza, RSV and Ebola virus disease.

Professor Helen McShane, Director of the NIHR Oxford Biomedical Research Centre, said: “I’d like to congratulate my colleagues for being named NIHR Senior Investigators. It is a very competitive award, so they should be immensely proud of this achievement. It is fantastic for them to receive recognition for the important research they’ve been carrying out.”

NIHR Senior Investigator status is awarded to researchers on the basis of their internationally excellent research, its quality and volume, its relevance to patients and the public, and its impact on improvements in healthcare and public health.

They receive a discretionary award of £20,000 per year of appointment to fund activities that support their research.

They hold their award for no more than two terms, to ensure turnover and to create opportunities for new researchers to participate in NIHR at senior level. The college of Senior Investigators is maintained at around 200 researchers in total.

On completion of a second successful term, Senior Investigators are awarded the title Senior Investigator Emeritus, which they hold as long as they are in substantive employment in England.

In this year’s awards, three Oxford BRC researchers have received the prestigious title of Senior Investigator Emeritus in recognition of the work they have carried out as a Senior Investigator and continue to do. They are:

  • Prof Andrew Carr, Nuffield Professor of Orthopaedic Surgery and Head of Department at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.  
  • Prof Andrew Farmer, Professor of General Practice at the Nuffield Department of Primary Care Health Sciences.
  • Prof Paul Klenerman, Sidney Truelove Professor of Gastroenterology at the Nuffield Department of Medicine.

Similar stories

Vaccine for TB receives a $1.5 million funding boost

The Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.

University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships

Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.